Rheumatoid Arthritis News and Research RSS Feed - Rheumatoid Arthritis News and Research

Rheumatoid arthritis (RA) is a chronic disease of the joints that can cause a disabling degree of pain and significantly interfere with an individual’s day-to-day living.

RA is an autoimmune disease, meaning the immune system, which is usually geared up to fight infection, attacks the lining of the joints, causing them to swell and become stiff and painful. Eventually, the joint itself can become damaged as well as the cartilage and surrounding bone. Any joint can be affected but most commonly the illness involves the hands, feet and wrists.

The condition is more common among women than men and usually affects people between the ages of 40 and 70, although it can affect people of any age.

Symptoms range from mild to severe and can flare-up suddenly and unpredictably, making the condition very difficult to live with.

The exact cause of rheumatoid arthritis is not yet fully understood but some research suggests that viruses and bacteria may be involved. RA cannot be cured but early diagnosis and treatment can help to manage symptoms and prevent disability.
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
Researchers one step closer to finding treatment for Alzheimer's, other forms of dementia

Researchers one step closer to finding treatment for Alzheimer's, other forms of dementia

There is no cure for Alzheimer's disease and other forms of dementia, but the research community is one step closer to finding treatment. [More]
XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown. [More]
Researchers working to develop new drugs for treating chronic inflammatory diseases

Researchers working to develop new drugs for treating chronic inflammatory diseases

Science and industry are collaborating to develop future pharmaceuticals for treating chronic inflammatory diseases. The medicines will combat immunological processes that have gone wrong. [More]
New version of drug successfully treats lupus in mice

New version of drug successfully treats lupus in mice

Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases. [More]
Chronic fatigue and rheumatoid arthritis: an interview with Ailsa Bosworth, CE, National Rheumatoid Arthritis Society

Chronic fatigue and rheumatoid arthritis: an interview with Ailsa Bosworth, CE, National Rheumatoid Arthritis Society

Chronic fatigue is about much more than merely feeling tired and when it is at its worst, people feel unable to do almost anything, so it can impact absolutely every area of their life. [More]
Brain network measures placebo effects in Parkinson's disease patients

Brain network measures placebo effects in Parkinson's disease patients

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Glenmark plans to set up new manufacturing facility at Monroe Corporate Center, USA

Glenmark Pharmaceuticals Ltd, a research-driven, global, integrated pharmaceutical company, plans to set up a new manufacturing facility in the US. [More]
Novagant releases GoldenCBD oil including capsules and liquids

Novagant releases GoldenCBD oil including capsules and liquids

Novagant Corp. is pleased to announce that in this month of July it will release its GoldenCBD™ oil that will be available in several forms, including capsules and liquids. It will be the answer for those Medical Cannabis Patients living outside Washington and Colorado. [More]
Researchers reveal molecular interplay between Roquin and RNA

Researchers reveal molecular interplay between Roquin and RNA

The Roquin protein, discovered in 2005, controls T-cell activation and differentiation by regulating the expression of certain mRNAs. In doing so, it helps to guarantee immunological tolerance and prevents immune responses against the body's own structures that can lead to autoimmune disease. [More]
Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. [More]
Study to understand molecular interplay between Roquin and RNA to treat autoimmune diseases

Study to understand molecular interplay between Roquin and RNA to treat autoimmune diseases

Scientists at the Helmholtz Zentrum München, the Ludwig-Maximilians University of Munich (LMU) and the Technische Universität München (TUM) have moved an important step closer to understanding molecular mechanisms of autoimmune diseases. [More]
Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD. [More]
Lower back pain not triggered by weather changes according to new study

Lower back pain not triggered by weather changes according to new study

Episodes of lower back pain are not triggered by changes in weather conditions, say Australian researchers. [More]
Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. [More]
Acute episodes of low back pain not linked to weather conditions

Acute episodes of low back pain not linked to weather conditions

Australian researchers reveal that sudden, acute episodes of low back pain are not linked to weather conditions such as temperature, humidity, air pressure, wind direction and precipitation. [More]
Keck Medicine of USC study identifies potential therapeutic target for inflammation

Keck Medicine of USC study identifies potential therapeutic target for inflammation

Molecular microbiologists from the Keck School of Medicine of the University of Southern California have discovered that mice lacking a specific component of the immune system are completely resistant to sepsis, a potentially fatal complication of infection. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
Researchers identify new genes that likely contribute to asthma

Researchers identify new genes that likely contribute to asthma

In a study published yesterday in the scientific journal Nature Immunology, a group at the La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new genes that likely contribute to asthma, a disease that currently affects over 200 million people world wide. [More]